HRSA’s 340B Rebate Model Is Moving Faster Than Many Expected: What Covered Entities Should Be Doing Now

The 340B Program has entered a period of unprecedented scrutiny.

For years, policymakers, manufacturers, covered entities and contract pharmacies have debated the future of the program. But recent developments suggest that federal regulators are no longer merely studying potential reforms—they are actively building the infrastructure necessary to implement them.

Most recently, the Health Resources and Services Administration (HRSA) signaled that it intends to move quickly toward implementation of a 340B rebate model pilot beginning in 2027 for certain drugs subject to Medicare price negotiations under the Inflation Reduction Act (IRA).

Although the pilot may initially apply only to a limited universe of products, healthcare organizations participating in the 340B Program should not underestimate its significance. The initiative may ultimately serve as a blueprint for broader transparency and reporting requirements across the program.

What Is the 340B Rebate Model?

Historically, covered entities have purchased eligible drugs at the discounted 340B ceiling price at the point of sale.

Under the proposed rebate model, manufacturers would instead provide the 340B discount through a retrospective rebate process for certain qualifying drugs.

The policy objective is relatively straightforward. The IRA prohibits manufacturers from providing duplicative price concessions on drugs that are already subject to Medicare negotiated prices or Medicare inflation rebate obligations. Regulators view the rebate model as a mechanism to help identify and prevent those duplicate discounts.

While the concept may appear narrow on its face, implementation of the model necessarily requires something that has long been at the center of 340B policy debates: significantly greater visibility into claims-level utilization data.

The Real Story Is Transparency

The most consequential aspect of the rebate model may not be the rebate itself. Rather, it is the increased transparency that accompanies it.

To administer a rebate-based system, manufacturers and regulators must have greater access to information regarding how drugs are dispensed, billed and utilized. As a result, the rebate model is likely to generate additional reporting obligations and data-sharing requirements for covered entities and their contract pharmacy partners.

For years, disputes involving duplicate discounts, diversion concerns, contract pharmacy arrangements and manufacturer restrictions have been driven in part by a lack of uniform visibility into 340B claims data.

The rebate model represents a significant shift in that dynamic.

Whether viewed as a compliance tool or an oversight mechanism, the practical result is likely to be the same: more data, more reporting and more scrutiny.

Contract Pharmacies Remain in the Spotlight

Healthcare organizations should also recognize that the rebate model is developing against the backdrop of ongoing disputes involving contract pharmacy arrangements.

Manufacturers continue to pursue claims-data initiatives and alternative distribution models designed to obtain greater insight into 340B utilization. At the same time, policymakers increasingly are examining the financial structure of certain contract pharmacy relationships and the role those arrangements play within the broader healthcare ecosystem.

As transparency initiatives expand, contract pharmacy arrangements will likely remain a focal point for regulators, manufacturers and policymakers alike.

Covered entities should expect continued questions regarding oversight, documentation, compliance controls and the use of 340B-generated savings.

Accountability Is Becoming a Central Theme

Perhaps the most important takeaway is that the policy conversation surrounding 340B is evolving.

Historically, many debates centered on manufacturer restrictions, contract pharmacy access and statutory interpretation. Those issues remain important. However, regulators and policymakers are increasingly focused on a different question:

How is the program operating in practice?

As reporting capabilities expand and more claims-level information becomes available, covered entities may face growing expectations to demonstrate compliance, document program integrity and articulate how 340B savings support patient care and access initiatives.

Organizations that proactively strengthen compliance programs, audit processes and data governance structures will be better positioned to respond to that environment.

Looking Ahead

The proposed rebate model may begin with a limited set of drugs subject to Medicare negotiated pricing, but stakeholders should view it as part of a much broader trend.

Federal agencies continue to focus on transparency, accountability and data collection across the healthcare industry. The 340B Program is no exception.

Whether the rebate model ultimately remains limited in scope or expands over time, the direction of travel appears increasingly clear: more reporting, more visibility and greater scrutiny of how the program operates.

For covered entities, health systems, federally qualified health centers, hospitals and contract pharmacy participants, now is the time to evaluate whether existing compliance and data infrastructure will be sufficient for the next phase of 340B oversight.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.